Researchers suggest Ozempic and Wegovy could influence hiring decisions and workplace productivity as more Americans take them.
Recap by typeshit. Full story at CNBC.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
The FDA approved weekly insulin Awiqli for children 10 and up with type 2 diabetes, while Lilly's retatrutide data adds pressure before Novo's nine-month numbers.
The posters cover baseline traits in the phase 3 VANQUISH-2 trial and cardiometabolic measures from the phase 2 VENTURE study, November 14 to 17.
Loading…